Roche’s Hemlibra has been growing at eye-catching speed. Now, the Swiss drugmaker has padded the drug’s case with a mountain of data, just as its plan to buy into hemophilia gene therapy hit some regulatory road bumps. More: Roche touts
read moreIonis and its RNAi drug Tegsedi got a head start with England’s NHS, putting the pressure on Alnylam’s rival med Onpattro. But now, the country’s drug cost watchdog has changed its mind and backed the Alnylam drug, too. More: Alnylam's
read moreHaemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly. More: Roche presents positive late-stage Hemlibra data Source: News
read moreCompanies are set to be paid based on the value the medicine brings to the NHS. More: AMR pushes NHS to trial ‘subscription-style’ payment model Source: News
read moreThe full findings of the study were presented during a late-breaking session at the 27th Congress of the International Society on Thrombosis and Haemostasis. More: Xarelto success in paediatric venous thromboembolism Source: News
read moreNICE issued the drug a preliminary ‘no’, back in December 2018. More: NICE Onpattro approval puts Alnylam back in hATTR running Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals